D.E. Shaw & Co
PCRX icon

D.E. Shaw & Co’s Pacira BioSciences PCRX Stock Holding History

D.E. Shaw & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.8M Sell
1,982,724
-57,203
-3% -$1.27M 0.03% 708
2025
Q4 		$52.8M Buy
2,039,927
+97,784
+5% +$2.33M 0.03% 674
2025
Q3 		$50M Sell
1,942,143
-311,222
-14% -$7.64M 0.03% 657
2025
Q2 		$53.9M Sell
2,253,365
-10,544
-0.5% -$266K 0.04% 542
2025
Q1 		$56.3M Buy
2,263,909
+6,435
+0.3% +$154K 0.05% 436
2024
Q4 		$42.5M Buy
2,257,474
+300,536
+15% +$5.28M 0.03% 640
2024
Q3 		$29.5M Buy
1,956,938
+1,476,508
+307% +$25.2M 0.03% 771
2024
Q2 		$13.7M Buy
480,430
+239,991
+100% +$6.83M 0.01% 1130
2024
Q1 		$7.03M Buy
240,439
+34,423
+17% +$1.06M 0.01% 1645
2023
Q4 		$6.95M Buy
206,016
+48,954
+31% +$1.43M 0.01% 1644
2023
Q3 		$4.82M Buy
157,062
+151,753
+2,858% +$5.47M 0.01% 1836
2023
Q2 		$213K Sell
5,309
-13,723
-72% -$567K ﹤0.01% 3720
2023
Q1 		$777K Buy
+19,032
New +$757K ﹤0.01% 3331
2022
Q2 		– Sell
-11,651
Closed -$889K – 5659
2022
Q1 		$889K Sell
11,651
-38,046
-77% -$2.54M ﹤0.01% 4008
2021
Q4 		$2.99M Sell
49,697
-30,036
-38% -$1.66M ﹤0.01% 2961
2021
Q3 		$4.46M Sell
79,733
-82,790
-51% -$4.77M ﹤0.01% 2213
2021
Q2 		$9.86M Sell
162,523
-436,006
-73% -$27.6M 0.01% 1510
2021
Q1 		$42M Sell
598,529
-259,427
-30% -$18.5M 0.04% 570
2020
Q4 		$51.3M Sell
857,956
-14,376
-2% -$842K 0.05% 487
2020
Q3 		$52.4M Sell
872,332
-98,053
-10% -$5.7M 0.05% 401
2020
Q2 		$50.9M Sell
970,385
-76,598
-7% -$3.2M 0.06% 352
2020
Q1 		$35.1M Sell
1,046,983
-81,025
-7% -$3.37M 0.05% 389
2019
Q4 		$51.1M Sell
1,128,008
-99,732
-8% -$4.24M 0.06% 379
2019
Q3 		$46.7M Sell
1,227,740
-20,833
-2% -$832K 0.06% 401
2019
Q2 		$54.3M Buy
1,248,573
+306,129
+32% +$13M 0.07% 351
2019
Q1 		$35.9M Buy
942,444
+570,237
+153% +$22.3M 0.05% 480
2018
Q4 		$16M Buy
372,207
+209,170
+128% +$9.76M 0.02% 804
2018
Q3 		$8.01M Buy
+163,037
New +$7.05M 0.01% 1242
2018
Q2 		– Sell
-19,616
Closed -$611K – 3838
2018
Q1 		$611K Sell
19,616
-2,284
-10% -$81.3K ﹤0.01% 2785
2017
Q4 		$1M Buy
21,900
+12,049
+122% +$478K ﹤0.01% 2572
2017
Q3 		$370K Buy
+9,851
New +$396K ﹤0.01% 3052
2016
Q1 		– Sell
-106,462
Closed -$8.18M – 3688
2015
Q4 		$8.18M Buy
106,462
+7,798
+8% +$442K 0.01% 1068
2015
Q3 		$4.05M Buy
+98,664
New +$6.04M 0.01% 1549
2015
Q2 		– Sell
-42,198
Closed -$3.75M – 3842
2015
Q1 		$3.75M Buy
42,198
+29,076
+222% +$2.95M 0.01% 1565
2014
Q4 		$1.16M Buy
+13,122
New +$1.24M ﹤0.01% 2712
2014
Q3 		– Sell
-82,082
Closed -$7.99M – 4314
2014
Q2 		$7.54M Buy
82,082
+24,543
+43% +$1.87M 0.01% 1312
2014
Q1 		$4.03M Buy
57,539
+43,883
+321% +$2.98M 0.01% 1751
2013
Q4 		$785K Sell
13,656
-60,654
-82% -$3.19M ﹤0.01% 3378
2013
Q3 		$3.57M Sell
74,310
-154,326
-67% -$5.62M 0.01% 1895
2013
Q2 		$6.63M Buy
+228,636
New +$6.61M 0.01% 1159

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's PCRX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Pacira BioSciences (PCRX) stake by 2.8% in Q1 2026, selling an estimated $1.27M and leaving 1,982,724 shares worth $44.8M. The position accounts for 0.03% of the portfolio, ranked #708.

D.E. Shaw & Co first reported a position in PCRX in Q2 2013 and has held it in 40 quarters since. The position peaked at $56.3M in Q1 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • D.E. Shaw & Co held 1,982,724 shares of Pacira BioSciences worth $44.8M as of Q1 2026.
  • D.E. Shaw & Co sold 57,203 Pacira BioSciences shares in Q1 2026, an estimated $1.27M.
  • Pacira BioSciences made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #708 holding.
  • D.E. Shaw & Co first reported a position in Pacira BioSciences in Q2 2013 and has held it in 40 quarters since.
  • D.E. Shaw & Co's Pacira BioSciences position peaked at $56.3M in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.